X

Drug Profile

LBP KP01

Alternative Names: LBP-KP01

Latest Information Update: 28 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Locus Biosciences
Class Antibacterials; Bacteriophages
Mechanism of Action Cell death stimulants; DNA damage stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Urinary tract infections

Most Recent Events

28 Dec 2024 No recent reports of development identified for preclinical development in Urinary-tract-infections in USA
10 Nov 2020 Locus Bioscience establishes grant from Biomedical Advanced Research and Development Authority for the development of LBP KP01 in Urinary tract infection
10 Nov 2020 Preclinical trials in Urinary tract infections in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com